PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ — In 2024, significant advancements in Cell and Gene Therapy (CGT) have been achieved. Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has been globally launched for treating solid tumors. PM359, the world’s first lead editing therapy, has been approved for clinical trials, marking a milestone in gene editing technology. The introduction of INT2104, the first in vivo edited CAR-T therapy, will expand the development pathway for CAR-T therapies by entering clinical trials.
Among this progress, opportunities and challenges have emerged. The focus is on exploring new frontiers in the promising but risky CGT market and navigating the path ahead with precision.
On November 20, 2024, the “2024 GenScript Biotech Global Forum” in London will convene leading global experts to discuss the future of CGT, driving industry progress and transformation.
The forum will feature Dr. James Wilson, a distinguished scientist in gene therapy, Miguel Forte, a prominent figure with expertise spanning academia, industry, and regulatory sectors, and Ying Huang, CEO of Legend Biotech, as a featured guest. The gathering of esteemed experts promises to stimulate innovative thinking and promote cross-sector collaboration, driving robust growth in the CGT industry. This forum aims to witness the birth of groundbreaking innovations and a new chapter in industry development.
As a leader in the biotech industry, GenScript is devoted to fostering dialogue and collaboration by providing a platform for global exchange to advance innovation in the CGT sector. GenScript has successfully hosted global forums in the past and aims to continue focusing on the latest developments in CGT through the London forum.
For more information about the forum and to register for free entry with the invitation code GS2024 by September 15, click the link provided.
Other Stories
Best time to book fall holiday travel: economist warns low prices won’t last